The State's Connecticut Innovations Commits $150,000 to ImStem Biotechnology of Farmington

“ImStem's work is not only important from a public health standpoint, but is part of a wider growing biotech industry that is creating well-paying, high-tech jobs,” said Mike Demicco (D-Farmington).

Connecticut Innovation, the state’s quasi-public authority responsible for growing businesses has committed funding totaling $150,000 through its Pre-Seed Fund to ImStem biotechnology startup venture.

ImStem Biotechnology Inc. is an emerging biotechnology company developing cell therapeutic products derived from human embryonic stem cells for use in tissue repair and treatment of neural, heart, vascular and blood system and autoimmune diseases.